Abstract
Background Lung cancer poses a serious threat to human health. Lung CT is widely used for lung tumor screening or initial diagnosis, while contrast-lung CT is extensively employed in lung tumor diagnosis. However, false-positive lung CT results can lead to misdiagnosis and incorrect surgery or treatment, while false-negative lung CT results can lead to missed diagnosis and delayed treatment. There is an urgent need to find convenient, cost-effective and non-invasive diagnostic methods to reduce the false-positive rate and false-positive rates of lung CT. The aim of this study was to evaluate the diagnostic value of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D, in lung cancer.
Patients and methods This study finally included 1250 subjects (the malignant group, n=1078; the benign group, n=172). Remaining serum samples from the subjects were collected and tested using the YiDiXie™ all-cancer detection kit, which was applied to assess the sensitivity and specificity of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D, respectively. Results: YiDiXie™-SS has a sensitivity of 97.5% (96.4% - 98.3%) and its specificity is 66.9% (59.5% - 73.5%). This means that YiDiXie™-SS has very high sensitivity and high specificity in lung tumors.YiDiXie™-HS has a sensitivity of 85.3% (83.0% - 87.2%) and its specificity is 83.1% (76.8% - 88.0%). This means that YiDiXie™-HS has high sensitivity and high specificity in lung tumors.YiDiXie™-D has a sensitivity of 73.9% (71.2% - 76.5%) and its specificity is 92.4% (87.5% - 95.5%). This means that YiDiXie™-D has high sensitivity and very high specificity in lung tumors.YiDiXie™-SS has a sensitivity of 98.2% (95% CI: 96.8% - 99.0%) and a specificity of 66.0% (95% CI: 51.7% - 77.8%) in patients with CT-positive tumors. This means that the application of YiDiXie™-SS reduces the CT false-positive rate by 66.0% (95% CI: 51.7% - 77.8%) with essentially no increase in malignancy underdiagnosis. The sensitivity of YiDiXie™-HS in CT negative patients was 84.2% (95% CI: 80.6% - 87.2%) and its specificity was 82.4% (95% CI: 74.8% - 88.1%). This means that the application of YiDiXie ™ -HS reduces the false-negative lung CT rate by 84.2% (95% CI: 80.6% - 87.2%). YiDiXie™-D has a sensitivity of 73.7% (70.1% - 77.1%) and a specificity of 93.6% (82.8% - 97.8%) in CT-positive patients. This means that YiDiXie ™ -D reduces the rate of CT false positives by 93.6% (82.8% - 97.8%). YiDiXie™-D has a sensitivity of 74.2% (70.1% - 78.0%) and a specificity of 92.0% (85.9% - 95.6%) in patients with a negative CT. This means that YiDiXie™-D reduces the CT false-negative rate by 74.2% (70.1% - 78.0%) while maintaining high specificity.
Conclusion YiDiXie™-SS provides extremely high sensitivity and high specificity in lung tumors. YiDiXie™-HS provides high sensitivity and high specificity in lung tumors. yiDiXie™-D provides high sensitivity and very high specificity in lung tumors. YiDiXie ™ -SS significantly reduces the rate of lung CT false positives with essentially no increase in delayed treatment of malignant tumors. YiDiXie™-HS significantly reduces the false-negative rate of lung CT. YiDiXie™-D can significantly reduce the false-positive rate of lung CT or significantly reduce the false-negative rate while maintaining high specificity. the YiDiXie™ test has important diagnostic value in lung cancer and is expected to solve the problems of “too high false-positive rate” and “too high false-negative rate” of lung CT.
Clinical trial number ChiCTR2200066840.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ChiCTR2200066840
Funding Statement
This work was supported by Shenzhen High-level Hospital Construction Fund, Clinical Research Project of Peking University Shenzhen Hospital (LCYJ2020002, LCYJ2020015, LCYJ2020020, LCYJ2017001).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Peking University Shenzhen Hospital gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The results were updated. Tabel 2-8 were reviesed.
Data Availability
All data produced in the present study are contained in the manuscript.
